Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.
BC-3781 is a novel semisynthetic pleuromutilin antimicrobial agent developed as an intravenous and oral therapy for acute bacterial skin and skin structure infections (ABSSSI) and respiratory tract infections (RTI). BC-3781 and comparator agents were tested by the broth microdilution method against 1,893 clinical Gram-positive organisms predominantly causing ABSSSI. BC-3781 exhibited potent activity against methicillin-resistant Staphylococcus aureus (MIC(50/90), 0.12/0.25 μg/ml), coagulase-negative staphylococci (MIC(50/90), 0.06/0.12 μg/ml), β-hemolytic streptococci (MIC(50/90), 0.03/0.06 μg/ml), viridans group streptococci (MIC(50/90), 0.12/0.5 μg/ml), and Enterococcus faecium (including vancomycin-nonsusceptible strains) (MIC(50/90), 0.12/2 μg/ml). Compared with other antibiotics in use for the treatment of ABSSSI, BC-3781 displayed the lowest MICs and only a minimal potential for cross-resistance with other antimicrobial classes.
JMI Laboratories, North Liberty, Iowa, USA. helio-sader@jmilabs.com
Helio S
HS
Sader
Douglas J
DJ
Biedenbach
Susanne
S
Paukner
Zrinka
Z
Ivezic-Schoenfeld
Ronald N
RN
Jones
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004224:Diterpenes / Q000494:pharmacology*; D015507:Drugs, Investigational; D016983:Enterococcus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D012867:Skin / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D013291:Streptococcus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D004224:Diterpenes; D015507:Drugs, Investigational; D014640:Vancomycin